China is the big unknown in Coloplast guidance, assesses Jefferies
The Chinese market features heavily in Coloplast’s expectations for the full-year 2022/2023, but prospects in the country have been shrouded in uncertainty due to the pandemic.
by marketwire, translated by daniel pedersen
China has posed a challenge to Coloplast due to a period of extensive pandemic shutdowns – and the country continues to feature as a large unknown factor in the medtech company’s guidance for 2022/2023, assesses investment bank Jefferies.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Coloplast CEO says no sign of recovery in China
For subscribers
